ACLY and neoplasm: Despite these advances, challenges remain: tumor-intrinsic heterogeneity (e.g., variable ATP-citrate lyase expression) may limit efficacy in ATP-citrate lyase-low tumors, and strain-specific microbial engineering (to boost pentanoate production) requires refinement to avoid interpatient variability.